drugset / Trial / NCT01959516

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

NCT01959516

Phase 4 Completed 124 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

This study purpose is to further study the profiles of glycopyrronium (NVA237) and tiotropium during the first hours after dosing and their impact on pulmonary function, COPD symptoms and ability to perform daily activities by the patient.

Timeline

Start
2014-02
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown Inhaled
Subject Tiotropium Other / unclassified Inhaled